Company News: Ananda Wellness; InhaleRx; Emyria; Global cann

Ananda Wellness Group

A former Flight Center marketing chief has been appointed to lead the expansion of Byron Bay-based Ananda Wellness Group.

In his role as Managing Director, Keith Stanley will work with Dr Jamie Rickcord, founder of Ananda Clinics, to create a “medical approach” to the business, with the aim “to add to the growing evidence base around the endocannabinoid medicine and using modern technologies”. interactive technology to improve patient outcomes”.

Further details of Ananda Wellness’ plans are expected to be released shortly.

Stanley is a former head of global marketing for Flight Center and former managing director of Stella Travel Services, which owned the now-defunct travel agency Harvey World Travel.

InhaleRx

Health technology company InhaleRx has named Cannvalate board member and co-founder Darryl Davies as chief executive officer.

Davies will step down as executive director, a position he has held since July 2021, to take on the role of part-time, $135,000-a-year CEO.

The company has also appointed Dr. Rob Jenny as Chief Scientific Officer. Jenny, a former Epsilon board member, comes from Cannvalate where he was head of business development.

Davies, who has 16 years of experience in psychology, harm minimization and health care commercialization, will oversee two clinical tracks in which the company is involved.

“I look forward to the next exciting chapter in InhaleRx’s development and will work closely with the highly skilled Board of Directors and management team to lead the execution of the company’s strategic plans throughout. of the life cycle of the two clinical trial programs,” he said.

“Additionally, I will focus on new opportunities to develop new inhaler drug/device therapies to address unmet clinical needs.

Meanwhile, plastic surgeon Dr. John Crock will join InhaleRx as non-executive director.

He will advise the company on the clinical aspects of the two trials.

Emyria

Nine sites in four states will conduct the Phase III clinical trial for Emyria’s cannabinoid drug EMD-RX5 as it pursues its bid to register an over-the-counter Schedule 3 product.

Double-blind, randomized, placebo-controlled study will target symptoms of psychological distress in patients with a history of chronic pain

Eight newly confirmed sites will join Hatherley Medical Center in WA to conduct the trial. The sites will now begin recruiting patients in partnership with Emyria’s patient onboarding operation, Emerald Clinics.

Emerald Clinics will help clinical sites recruit patients for the phase III trial

Four other sites have been identified for qualification if necessary.

A total of 300 participants between the ages of 18 and 70 will receive either 50 mg of Emyria’s EMD-RX5 capsule, 150 mg, or a placebo. It will be administered over a month.

Emyria chief executive Dr Michael Winlo said there was “exceptional demand” from clinical sites wanting to participate in the trial.

“We view this as a strong sign that there is strong clinical interest in our unique Ultra-Pure CBD capsule and strong patient need for new treatment options for our target indication – symptoms of psychological distress,” a- he declared. “The eight additional clinical trial sites are now set to begin patient recruitment across Australia, with our trial drug EMD-RX5 ready for distribution over the next few weeks.

“At the same time, we are advancing commercialization discussions and look forward to providing more EMD-RX5 registration updates in future announcements.”

Global cann

Cann Global is set to acquire a public company after being suspended.

The listed company has suspended its activities “pending the publication of an announcement concerning a proposed acquisition”.

The suspension will remain in place until Tuesday, October 4, at the earliest, or until announced.

Cann Global shares were trading at $0.021 at the time of the suspension.

Karen J. Nelson